Abstract
Pharmaceutical companies are reluctant to invest in research and development (R&D) of products for neglected tropical diseases (NTDs) mainly due to the low ability-to-pay of health insurance systems and of potential consumers. The available preventive and curative interventions for NTDs mostly rely on old technologies and products that are often not adequate. Moreover, NTDs mostly affect populations living in remote rural areas and conflict zones, thereby hampering access to healthcare. The challenges posed by NTDs have led to the proliferation of a variety of public-private partnerships (PPPs) in the last decades. We conducted a systematic review to assess the functioning and impact of these partnerships on the development of and access to better technologies for NTDs. Our systematic review revealed a clear lack of empirical assessment of PPP5: we could not find any impact evaluation analyses, while these are crucial to realize the full potential of PPP5 and to progress further towards NTDs elimination. (C) 2017 Elsevier B.V. All rights reserved.
Original language | English |
---|---|
Journal | Health Policy |
Volume | 121 |
Issue number | 7 |
Pages (from-to) | 745-754 |
Number of pages | 10 |
ISSN | 0168-8510 |
DOIs | |
Publication status | Published - 2017 |
Keywords
- Public-private partnerships
- Neglected tropical diseases
- Health economics
- Public health
- Research and development
- PRODUCT DEVELOPMENT PARTNERSHIPS
- RESEARCH-AND-DEVELOPMENT
- DRUG DISCOVERY
- PHARMACEUTICAL INNOVATION
- RESEARCH CAPACITY
- HUMAN HOOKWORM
- HEALTH EQUITY
- VACCINES
- ONCHOCERCIASIS
- AMERICA